Clinical Trials on Metastatic Prostate Cancer

Total 56227 results

AstraZeneca
Merck Sharp & Dohme LLC

Completed

Ph II Study to Evaluate Olaparib With Abiraterone in Treating Metastatic Castration Resistant Prostate Cancer.

Metastatic Castration-resistant Prostate Cancer

Belgium, France, Italy, Netherlands, Poland, United States, Canada, Czechia, Russian Federation, United Kingdom, Spain
Amgen

Terminated

Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United States, Sweden, Spain, United Kingdom, Australia, Denmark
Veru Inc.

Terminated

To Evaluate Safety and Tolerability of VERU-111 in Men With Advanced Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

United States
Novo Nordisk A/S

Terminated

A Study of FT-7051 in Men With MCRPC

Metastatic Castration-resistant Prostate Cancer

United States
Swiss Group for Clinical Cancer Research

Active, not recruiting

Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer

Switzerland
Institute of Cancer Research, United Kingdom
AstraZeneca; Astellas Pharma Inc; Prostate Cancer UK

Terminated

Combination Study of AZD5069 and Enzalutamide. (ACE)

Metastatic Castration Resistant Prostate Cancer

United Kingdom, Switzerland
Peter MacCallum Cancer Centre, Australia
United States Department of Defense; Advanced Accelerator Applications; Australian... and other collaborators

Active, not recruiting

In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy (UpFrontPSMA)

Metastatic Hormone Naive Prostate Cancer

Australia
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Completed

SHR7390 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

China
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Withdrawn

Image-Guided Biopsies in Identifying Mechanisms of Resistance in Participants With Metastatic Castration Resistant Prostate Cancer Undergoing Radioligand Therapy

Castration-Resistant Prostate Carcinoma | Metastatic Prostate Carcinoma | Stage IV Prostate Cancer
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy

Prostate Cancer | Metastatic Cancer

United States
Cancer Trials Ireland

Completed

Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2

Prostate Cancer | Metastatic Cancer

Ireland
University Hospital Birmingham

Completed

Docetaxel and Prednisolone With or Without Zoledronic Acid and/or Strontium Chloride Sr 89 in Treating Patients With Prostate Cancer Metastatic to Bone That Has Not Responded to Hormone Therapy

Prostate Cancer | Metastatic Cancer

United Kingdom
Syntrix Biosystems, Inc.
National Cancer Institute (NCI)

Recruiting

Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (SYNERGY-201)

Metastatic Castration-resistant Prostate Cancer

United States
H. Lee Moffitt Cancer Center and Research Institute

Recruiting

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

Metastatic Castration-resistant Prostate Cancer

United States
Bayer

Recruiting

A Study to Learn How Safe the Study Treatment Actinium-225-macropa-pelgifatamab (BAY3546828) is, How it Affects the Body, How it Moves Into, Through and Out of the Body, and About Its Anticancer Activity in Men With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United Kingdom, Netherlands, Finland
Fusion Pharmaceuticals Inc.

Recruiting

Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (TATCIST)

Metastatic Castration Resistant Prostate Cancer

United States
Aragon Pharmaceuticals, Inc.

Active, not recruiting

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms | Metastatic Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, United Kingdom
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Active, not recruiting

A Study of Opevesostat (MK-568)4 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)

Prostatic Neoplasms | Metastatic Castration-Resistant Prostate Cancer

Japan
Bayer

Active, not recruiting

Observational Study for the Evaluation of Long-term Safety of Radium-223 Used for the Treatment of Metastatic Castration Resistant Prostate Cancer (REASSURE)

Metastatic Castration-resistant Prostate Cancer

United States, Austria, Czechia, Israel, Italy, Germany, United Kingdom, France, Mexico, Belgium, Canada, Colombia, Greece, Luxembourg, Netherlands, Spain, Denmark, Sweden, Argentina, Portugal
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetics, Inc.; Foundation Medicine, Inc.

Active, not recruiting

Clinical Study to Assess the Efficacy and Safety of Olaparib in Chinese Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment With a New Hormonal Agent and Have BRCA1/2 Mutations

Metastatic Castration-resistant Prostate Cancer

China
POINT Biopharma, a wholly owned subsidiary of Eli...

Active, not recruiting

Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment (SPLASH)

Metastatic Castration-Resistant Prostate Cancer

United States, Canada, Netherlands, Sweden, France, United Kingdom
Hinova Pharmaceuticals Aus Pty Ltd

Completed

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Australia
Dana-Farber Cancer Institute
Eli Lilly and Company; Genentech, Inc.

Active, not recruiting

Abemaciclib With or Without Atezolizumab for mCRPC

Prostate Cancer | Metastatic Castration-resistant Prostate Cancer

United States
Australian and New Zealand Urogenital and Prostate...
Astellas Pharma Inc; Endocyte; Prostate Cancer Research Alliance; National Health...

Active, not recruiting

Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer (ENZA-p)

Metastatic Castration-Resistant Prostate Cancer

Australia
Pfizer
In Expanded Access, treating physicians are the Sponsors

Available

Pre-approval Single-patient Expanded Access for Talazoparib (PF-06944076)

Metastatic Castration-Resistant Prostate Cancer
AstraZeneca
Merck Sharp & Dohme LLC; Myriad Genetics, Inc.; Foundation Medicine, Inc.

Completed

Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Metastatic Castration-resistant Prostate Cancer

United States, Canada, Denmark, Germany, Italy, Netherlands, Norway, Spain, Argentina, Taiwan, France, Korea, Republic of, Brazil, Japan, Turkey, United Kingdom, Austria, Australia, Israel, Sweden
AB Science

Completed

Masitinib Plus Docetaxel in Metastatic Castration-resistant Prostate Cancer

Metastatic Castrate Resistant Prostate Cancer

Italy, Russian Federation, India, Canada, France, Malaysia
Université de Sherbrooke
Canadian Cancer Society (CCS); Fonds de la Recherche en Santé du Québec; Merck... and other collaborators

Completed

3TMPO (Triple-Tracer Strategy Against Metastatic Prostate Cancer

Metastatic Castration-resistant Prostate Cancer

Canada
Tceleron Therapeutics, Inc.

Terminated

A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Metastatic Castration-resistant Prostate Cancer

United States
National University Hospital, Singapore
National University of Singapore

Active, not recruiting

Effect of Low-dose 500 mg Abiraterone Acetate in Treatment of Metastatic Prostate Cancer Patients

Prostate Cancer | Metastatic Cancer | Castration-resistant Prostate Cancer | Hormone Sensitive Prostate Cancer

Singapore
UNICANCER
National Cancer Institute, France

Recruiting

Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases (STEREO-OS)

Metastatic Lung Cancer | Metastatic Breast Cancer | Bone Metastases | Metastatic Prostate Cancer

France
Roswell Park Cancer Institute
University of Pittsburgh

Completed

Dendritic Cell (DC)-Based Vaccines Loaded With Allogeneic Prostate Cell Lines in Combination With Androgen Ablation in Patients With Prostate Cancer

Prostate Cancer | Prostate Neoplasms | Cancer of the Prostate | Neoplasms, Prostate | Prostatic Cancer | Neoplasms, Prostatic | Cancer of Prostate

United States
Bayer

Recruiting

First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA)

Advanced Metastatic Castration-resistant Prostate Cancer | Prostate Specific Membrane Antigen (PSMA) Expression

Canada, United Kingdom, Belgium
SL VAXiGEN

Recruiting

Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Korea, Republic of
Azienda Unità Sanitaria Locale Reggio Emilia

Recruiting

Rehabilitation Intervention to Prevent Adverse Events Related to Androgen-deprivation Therapy (ADT) in Patients With Metastatic Prostate Cancer (PCa): a Single Arm Feasibility Study (ReCaP Study) (ReCaP)

Rehabilitation | Metastatic Prostate Cancer (PCa) in ADT

Italy
Yantai LNC Biotechnology Singapore PTE. LTD.

Not yet recruiting

The Safety and Dosimetry Study of 177Lu-LNC1003 Injection

Metastatic Castration-resistant Prostate Cancer, mCRPC
Merck Sharp & Dohme LLC
Orion Corporation, Orion Pharma

Recruiting

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Prostatic Neoplasms | Metastatic Castration-resistant Prostate Cancer (mCRPC)

Australia, Germany, United States, Puerto Rico, Israel, Korea, Republic of, Taiwan, China, Costa Rica, Guatemala, Spain, France, Hong Kong, Portugal, Romania, Chile, Czechia, Hungary, Italy, Sweden, Turkey, United Kingdom, Estonia, Ir... and more
University of Oklahoma
Dendreon

Recruiting

Sipuleucel-T Based Autologous Cellular Immunotherapy for Advanced Prostate Cancer (OUSCCEXCITE)

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Peter MacCallum Cancer Centre, Australia

Recruiting

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer (LuCAB)

Metastatic Castration-resistant Prostate Cancer | mCRPC

Australia
Peter MacCallum Cancer Centre, Australia

Recruiting

177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate Cancer (LuPARP)

Metastatic Castration Resistant Prostate Cancer (mCRPC)

Australia
Canadian Cancer Trials Group
Canadian Cancer Society (CCS)

Recruiting

Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer (PLATON)

Prostate Cancer Metastatic

Canada
Bayer

Active, not recruiting

An Observational Cohort Study to Describe and Compare the Use of Darolutamide, Enzalutamide and Apalutamide and How Well These Work in Men With Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) in Real World Settings (DEAR-EXT)

Non-metastatic Castration-resistant Prostate Cancer

United States
Bayer

Active, not recruiting

Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer (mCRPC)

United States, United Kingdom, Finland
Astellas Pharma Inc

Active, not recruiting

An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants

Progressive Metastatic Prostate Cancer

China, Hong Kong, Korea, Republic of, Taiwan
Centre hospitalier de l'Université de Montréal...
Genzyme, a Sanofi Company

Active, not recruiting

Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide (CABPOSTAAT)

Metastatic Prostate Cancer

Canada
Bayer

Completed

An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings (DEAR)

Non-metastatic Castration-resistant Prostate Cancer

United States
Fortis Therapeutics, Inc.

Completed

A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Prostate Cancer Metastatic

United States
Accutar Biotechnology Inc

Terminated

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

Metastatic Castration Resistant Prostate Cancer

China
Tianjin Medical University Second Hospital
The Second Hospital of Hebei Medical University; Tianjin Medical University... and other collaborators

Completed

Tissue Predictors of Abiraterone Benefit

Metastatic Castration-resistant Prostate Cancer

China
Janssen Research & Development, LLC

Approved for marketing

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Metastatic Castration-resistant Prostate Cancer

Brazil, Austria, Estonia, Israel, Mexico

Clinical Trials on Metastatic Prostate Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations